Please use this identifier to cite or link to this item:
|Title:||Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.|
|Authors:||Cebon, Jonathan S;Knights, Ashley J;Ebert, Lisa;Jackson, Heather M;Chen, Weisan|
|Affiliation:||Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg VIC 3084, Australia|
|Citation:||Expert Review of Vaccines; 9(6): 617-29|
|Abstract:||The rigorous evaluation of cancer vaccination requires evidence of benefit to patients with cancer or those at risk of relapse from the disease. Clinical trials are expensive and require considerable human and clinical resources in order to demonstrate this benefit. In the era of defined cancer antigens, it is possible to evaluate immunogenic targets, and assess the quality and magnitude of immune responses against these antigens following vaccination. Analyzing these surrogate end points complements clinical assessment and provides a depth of understanding to better inform trial evaluation and design. We have used the immunogenic cancer testis antigen NY-ESO-1 as a model antigen. This article summarizes our experience in monitoring immunity against NY-ESO-1.|
|Internal ID Number:||20518717|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.